MCID: LPD008
MIFTS: 59

Lipid Metabolism Disorder

Categories: Metabolic diseases

Aliases & Classifications for Lipid Metabolism Disorder

MalaCards integrated aliases for Lipid Metabolism Disorder:

Name: Lipid Metabolism Disorder 12 14
Disorder of Fatty Acid Metabolism 28 69
Lipid Metabolism Disorders 40 69
Dyslipidemia 12 51
Abnormality of Lipid Metabolism 28
Lipid Metabolism, Inborn Errors 41
Fatty Acid Metabolism Disorder 12
Dyslipidemias 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3146
MeSH 41 D008052
ICD10 32 E71.3

Summaries for Lipid Metabolism Disorder

MedlinePlus : 40 Metabolism is the process your body uses to make energy from the food you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system (enzymes) break the food parts down into sugars and acids, your body's fuel. Your body can use this fuel right away, or it can store the energy in your body tissues. If you have a metabolic disorder, something goes wrong with this process. Lipid metabolism disorders, such as Gaucher disease and Tay-Sachs disease, involve lipids. Lipids are fats or fat-like substances. They include oils, fatty acids, waxes, and cholesterol. If you have one of these disorders, you may not have enough enzymes to break down lipids. Or the enzymes may not work properly and your body can't convert the fats into energy. They cause a harmful amount of lipids to build up in your body. Over time, that can damage your cells and tissues, especially in the brain, peripheral nervous system, liver, spleen, and bone marrow. Many of these disorders can be very serious, or sometimes even fatal. These disorders are inherited. Newborn babies get screened for some of them, using blood tests. If there is a family history of one of these disorders, parents can get genetic testing to see whether they carry the gene. Other genetic tests can tell whether the fetus has the disorder or carries the gene for the disorder. Enzyme replacement therapies can help with a few of these disorders. For others, there is no treatment. Medicines, blood transfusions, and other procedures may help with complications.

MalaCards based summary : Lipid Metabolism Disorder, also known as disorder of fatty acid metabolism, is related to chylomicron retention disease and sitosterolemia. An important gene associated with Lipid Metabolism Disorder is RBP4 (Retinol Binding Protein 4), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Simvastatin and Fenofibrate have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and endothelial, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Disease Ontology : 12 An inherited metabolic disorder that involves the creation and degradation of lipids.

Wikipedia : 72 Lipid metabolism is the synthesis and degradation of lipids in cells. Lipid metabolism is the break down... more...

Related Diseases for Lipid Metabolism Disorder

Diseases related to Lipid Metabolism Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 chylomicron retention disease 31.7 APOA1 APOB MTTP
2 sitosterolemia 31.6 APOB HMGCR MTTP
3 hyperlipoproteinemia, type v 31.6 APOA5 APOE INS LPL
4 lipodystrophy, familial partial, type 2 31.5 INS LEP
5 hypoalphalipoproteinemia, primary 31.5 APOA1 APOB APOC3 CETP LIPC LPL
6 prediabetes syndrome 31.0 ADIPOQ APOB COG2 CRP INS LEP
7 hypolipoproteinemia 30.9 APOA1 APOB APOE LPA LPL MTTP
8 hyperlipoproteinemia, type iv 30.3 APOA1 APOA5 APOB APOC3 APOE LIPC
9 hyperlipoproteinemia, type iii 30.1 APOA1 APOA5 APOB APOE CETP COG2
10 ischemic heart disease 29.6 APOA1 APOB APOE CRP LPL
11 familial hyperlipidemia 29.4 APOA1 APOB APOC3 APOE CETP COG2
12 heart disease 29.0 ADIPOQ APOA5 APOB APOE CRP HMGCR
13 coronary heart disease 1 26.3 ADIPOQ APOA1 APOA5 APOB APOC3 APOE
14 body mass index quantitative trait locus 11 26.1 ADIPOQ APOA1 APOA5 APOB APOC3 APOE
15 citrullinemia, type ii, neonatal-onset 11.6
16 fatty liver disease, nonalcoholic 1 11.3
17 hyperlipoproteinemia, type i 11.1
18 aromatase deficiency 11.0
19 bietti crystalline corneoretinal dystrophy 10.8
20 acyl-coa dehydrogenase, medium-chain, deficiency of 10.8
21 acyl-coa dehydrogenase, short-chain, deficiency of 10.8
22 acyl-coa dehydrogenase, very long-chain, deficiency of 10.8
23 carnitine palmitoyltransferase i deficiency 10.8
24 tay-sachs disease 10.8
25 barth syndrome 10.8
26 carnitine palmitoyltransferase ii deficiency, infantile 10.8
27 steroid inherited metabolic disorder 10.8
28 gaucher's disease 10.8
29 gallbladder disease 1 10.8
30 lipodystrophy, familial partial, type 3 10.8
31 lipodystrophy, familial partial, type 6 10.8
32 xanthoma disseminatum 10.5 APOB APOE
33 malignant otitis externa 10.5 CRP INS
34 acquired generalized lipodystrophy 10.4 ADIPOQ LEP
35 hypercholesterolemia, autosomal dominant, type b 10.4 APOB APOE
36 lipase deficiency, combined 10.4 LIPC LPL
37 defective apolipoprotein b-100 10.4 APOB APOE HMGCR
38 endocrine pancreas disease 10.4 ADIPOQ INS LEP
39 acanthosis nigricans 10.4 ADIPOQ INS LEP
40 familial partial lipodystrophy 10.4 INS LEP PPARG
41 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.4 CRP INS LEP
42 familial lcat deficiency 10.4 APOA1 APOE
43 severe pre-eclampsia 10.4 ADIPOQ LEP RBP4
44 fetal macrosomia 10.3 APOA1 APOB INS LEP
45 obesity-hypoventilation syndrome 10.3 ADIPOQ LEP
46 idiopathic edema 10.3 ADIPOQ INS PPARA PPARG
47 dysbaric osteonecrosis 10.3 APOA1 APOB SERPINE1
48 3-hydroxyacyl-coa dehydrogenase deficiency 10.3 ADIPOQ INS PPARA PPARG
49 lipoprotein glomerulopathy 10.3 APOB APOE LPA
50 nonalcoholic steatohepatitis 10.3 ADIPOQ INS LEP PPARA

Comorbidity relations with Lipid Metabolism Disorder via Phenotypic Disease Network (PDN):


Chronic Myocardial Ischemia Hypertension, Essential
Intermediate Coronary Syndrome Ischemic Heart Disease

Graphical network of the top 20 diseases related to Lipid Metabolism Disorder:



Diseases related to Lipid Metabolism Disorder

Symptoms & Phenotypes for Lipid Metabolism Disorder

GenomeRNAi Phenotypes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.65 APOE CETP HMGCR LIPC LPA LPL
2 Increased LDL uptake GR00340-A-1 8.8 APOE LPL APOA1

MGI Mouse Phenotypes related to Lipid Metabolism Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.19 APOA1 LEP APOA5 APOB LIPC APOE
2 cardiovascular system MP:0005385 10.18 APOA1 LEP APOB APOE LPL MTTP
3 growth/size/body region MP:0005378 10.1 ADIPOQ INS LEP APOB APOE LPL
4 adipose tissue MP:0005375 10.01 INS LEP APOE LPL ADIPOQ PPARG
5 integument MP:0010771 9.81 ADIPOQ INS APOA1 LEP APOE LPL
6 liver/biliary system MP:0005370 9.73 APOA1 LEP APOB APOE LPL MTTP
7 muscle MP:0005369 9.28 INS LEP APOB APOE LPL ADIPOQ

Drugs & Therapeutics for Lipid Metabolism Disorder

Drugs for Lipid Metabolism Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 644)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
2
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Phase 1 49562-28-9 3339
3
Cilostazol Approved, Investigational Phase 4,Phase 1 73963-72-1 2754
4
Probucol Approved, Investigational Phase 4,Phase 3 23288-49-5 4912
5
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1 163222-33-1 150311
6
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 4091 14219
7
Fluvastatin Approved Phase 4,Phase 3,Phase 2 93957-54-1 1548972
8
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
9
Thrombin Approved, Investigational Phase 4
10
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
11
Pravastatin Approved Phase 4,Phase 2,Phase 3,Phase 1 81093-37-0 54687
12
Saxagliptin Approved Phase 4 361442-04-8 11243969
13
Abacavir Approved, Investigational Phase 4,Phase 2 136470-78-5 441300 65140
14
Lamivudine Approved, Investigational Phase 4,Phase 2 134678-17-4 60825
15
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
16
Lopinavir Approved Phase 4,Phase 2,Phase 1 192725-17-0 92727
17
Nevirapine Approved Phase 4,Phase 2 129618-40-2 4463
18
Zidovudine Approved Phase 4,Phase 2 30516-87-1 35370
19
Pitavastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 147511-69-1, 147526-32-7 5282452 6366718
20
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
21
Lovastatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75330-75-5 53232
22
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
23
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 128794-94-5 5281078
24
Mycophenolic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 24280-93-1 446541
25
Bezafibrate Approved, Investigational Phase 4,Phase 3,Phase 2 41859-67-0 39042
26
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
27
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 1 154598-52-4 64139
28
Darunavir Approved Phase 4,Phase 1 635728-49-3, 206361-99-1 213039
29
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 1 144701-48-4 65999
30 Fenofibric acid Approved Phase 4,Phase 3,Phase 1 42017-89-0
31
Gemfibrozil Approved Phase 4,Phase 1 25812-30-0 3463
32
Hydroxocobalamin Approved Phase 4,Phase 1,Phase 2 13422-51-0 5460373 44475014 11953898
33
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
34
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1 88150-42-9 2162
35
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
36
Loperamide Approved Phase 4 53179-11-6 3955
37
Colestipol Approved Phase 4 26658-42-4, 50925-79-6 62816
38
Everolimus Approved Phase 4,Phase 1 159351-69-6 6442177
39
Sirolimus Approved, Investigational Phase 4,Phase 1 53123-88-9 46835353 6436030 5284616
40
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1 137862-53-4 60846
41
Acarbose Approved, Investigational Phase 4,Phase 3 56180-94-0 441184
42
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
43
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 122320-73-4 77999
44
Coal tar Approved Phase 4,Phase 2,Phase 1 8007-45-2
45
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
46
Mannitol Approved, Investigational Phase 4,Early Phase 1 69-65-8 6251 453
47
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
48
Bexarotene Approved, Investigational Phase 4 153559-49-0 82146
49
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
50
Fosamprenavir Approved Phase 4,Phase 3,Phase 1,Phase 2 226700-79-4 131536

Interventional clinical trials:

(show top 50) (show all 2500)

# Name Status NCT ID Phase Drugs
1 Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin Unknown status NCT01613729 Phase 4 Rosuvastatin 5 mg;Rosuvastatin 10 mg
2 An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin Unknown status NCT00678743 Phase 4 Omacor + simvastatin
3 Nutraceuticals to Improve Lipid Profile in European Countries Unknown status NCT01649986 Phase 4 Nutraceuticals (Armolipid Plus)
4 Treatment of Hyperlipidemia and Sexual Dysfunction Unknown status NCT00923676 Phase 4 fenofibrate;Rosuvastatin;fenofibrate + rosuvastatin
5 To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Unknown status NCT02098460 Phase 4 Atorvastatin, Probucol, Cilostazol
6 Probiotic BIO-25 as a Supplement to Statins for the Treatment of Hypercholesterolemia Unknown status NCT01849185 Phase 4
7 The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels Unknown status NCT01712867 Phase 4
8 Lovaza Mechanisms of Action Unknown status NCT01301794 Phase 4
9 Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia Unknown status NCT00972829 Phase 4 Rosuvastatin;Ezetimibe
10 Triglyceride Lowering Study Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
11 Trial to Assess the Effects of P-OM3 on LDL-C in Subjects With Primary Hypercholesterolemia Unknown status NCT00746811 Phase 4 P-OM3;Placebo
12 Fluvastatin After Heart Transplantation Unknown status NCT00421005 Phase 4 fluvastatin
13 Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy? Unknown status NCT00295373 Phase 4 Rosuvastatin
14 Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia Unknown status NCT01010516 Phase 4 High-dose rosuvastatin;Statin plus fenofibrate;Statin plus niacin ER/laropiprant
15 Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
16 Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study) Unknown status NCT02035644 Phase 4 Jinlida granules;placebo granules
17 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
18 Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
19 The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients Unknown status NCT00758927 Phase 4 Omega-3 acid 4 grams per day;Placebo control
20 Japanese Primary Prevention Project With Aspirin Unknown status NCT00225849 Phase 4 Aspirin
21 Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia Unknown status NCT01480687 Phase 4 Ciprofibrate
22 Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes Unknown status NCT01322711 Phase 4 Atorvastatin;Placebo
23 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
24 The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
25 Effect of Rosuvastatin Therapy on HDL2 Level Unknown status NCT02593487 Phase 4 Rosuvastatin 10mg/d group;Rosuvastatin 20mg/d group
26 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients Unknown status NCT00135460 Phase 4 nucleoside analogue sparing HAART regimen
27 Effects of DPP-4 Inhibition on Triglycerides Unknown status NCT01527747 Phase 4 Saxagliptin
28 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Unknown status NCT01382277 Phase 4 Rosuvastatin
29 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT) Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
30 Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH) Unknown status NCT00885872 Phase 4 Rosuvastatin (Crestor)
31 Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Unknown status NCT00843661 Phase 4 ezetimibe;fenofibrate;pravastatin
32 Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease Unknown status NCT00487630 Phase 4 recombinant alpha-galactosidase A
33 A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
34 SHARE: Simple HAART With Abacavir, Reyataz, and Epivir Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
35 The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control Unknown status NCT00282659 Phase 4 magnesium L-lactate
36 Rajavithi Health Promotion Project (Population Base Cohort) Unknown status NCT00368095 Phase 4
37 Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
38 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
39 Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED) Completed NCT00651963 Phase 4 ezetimibe
40 Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia Completed NCT01551173 Phase 4 Fluvastatin sodium
41 Pharmacological Regulation of Fat Transport in Metabolic Syndrome Completed NCT00632840 Phase 4 Atorvastatin and fenofibrate
42 Regulation of Lipoprotein Transport in Metabolic Syndrome Completed NCT00841217 Phase 4 GW501516;placebo pill
43 Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes Completed NCT02689765 Phase 4
44 Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study Completed NCT00701727 Phase 4 ezetimibe;Placebo
45 Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects Completed NCT01385020 Phase 4 Gemfibrozil & red yeast rice (LipoCol)
46 Effect of Polyvitaminics (Pyridoxine Hydrochloride, Folic Acid and Cyanocobalamin) in the Concentration of Homocysteine and Lipid Profile in Postmenopausal Women: a Randomized Controlled, Double-blind Clinical Trial Completed NCT03221816 Phase 4 Tenavit®;Placebo Oral Tablet
47 Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) Completed NCT02642159 Phase 4 ALIROCUMAB SAR236553 (REGN727);placebo;statins;ezetimibe;fenofibrate;nicotinic acid;omega-3 fatty acids
48 Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir Completed NCT02442700 Phase 4 pitavastatin;placebo
49 The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients Completed NCT02103049 Phase 4 Ezetimibe
50 A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia Completed NCT02057302 Phase 4 Xuezhikang capsule

Search NIH Clinical Center for Lipid Metabolism Disorder

Cochrane evidence based reviews: lipid metabolism, inborn errors

Genetic Tests for Lipid Metabolism Disorder

Genetic tests related to Lipid Metabolism Disorder:

# Genetic test Affiliating Genes
1 Disorder of Fatty Acid Metabolism 28
2 Abnormality of Lipid Metabolism 28

Anatomical Context for Lipid Metabolism Disorder

MalaCards organs/tissues related to Lipid Metabolism Disorder:

38
Heart, Liver, Endothelial, Testes, Bone, Kidney, Bone Marrow

Publications for Lipid Metabolism Disorder

Articles related to Lipid Metabolism Disorder:

(show all 32)
# Title Authors Year
1
Maternal chromium restriction modulates miRNA profiles related to lipid metabolism disorder in mice offspring. ( 28669221 )
2017
2
Magnesium isoglycyrrhizinate blocks fructose-induced hepatic NF-I_B/NLRP3 inflammasome activation and lipid metabolism disorder. ( 28526339 )
2017
3
Protective effects of allicin on 1,3-DCP-induced lipid metabolism disorder in HepG2 cells. ( 29169723 )
2017
4
Association of SREBP2 gene polymorphisms with the risk of osteonecrosis of the femoral head relates to gene expression and lipid metabolism disorders. ( 28901487 )
2017
5
Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4I+ miR122 Pathway. ( 27011261 )
2016
6
Higher PDCD4 expression is associated with obesity, insulin resistance, lipid metabolism disorders, and granulosa cell apoptosis in polycystic ovary syndrome. ( 26868993 )
2016
7
HNF-4I+ regulated miR-122 contributes to development of gluconeogenesis and lipid metabolism disorders in Type 2 diabetic mice and in palmitate-treated HepG2 cells. ( 27592052 )
2016
8
Oral tributyrin prevents endotoxin-induced lipid metabolism disorder. ( 28531464 )
2015
9
[Genetically determined lipid metabolism disorders due to oral intake of technogenic hyperchlorination products]. ( 26596112 )
2015
10
L-Carnitine intake prevents irregular feeding-induced obesity and lipid metabolism disorder. ( 25445284 )
2015
11
Angelica sinensis polysaccharide regulates glucose and lipid metabolism disorder in prediabetic and streptozotocin-induced diabetic mice through the elevation of glycogen levels and reduction of inflammatory factors. ( 25630053 )
2015
12
Oral Exposure of Mice to Carbendazim Induces Hepatic Lipid Metabolism Disorder and Gut Microbiota Dysbiosis. ( 26071454 )
2015
13
Yhhu981, a novel compound, stimulates fatty acid oxidation via the activation of AMPK and ameliorates lipid metabolism disorder in ob/ob mice. ( 25732571 )
2015
14
Danqi Pill regulates lipid metabolism disorder induced by myocardial ischemia through FATP-CPTI pathway. ( 25885422 )
2015
15
Ameliorating effect of mother tincture of Syzygium jambolanum on carbohydrate and lipid metabolic disorders in streptozotocin-induced diabetic rat: Homeopathic remedy. ( 23633838 )
2013
16
Green tea extract containing a highly absorbent catechin prevents diet-induced lipid metabolism disorder. ( 24067358 )
2013
17
Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy. ( 22213519 )
2012
18
Abnormal barrier function in the pathogenesis of ichthyosis: therapeutic implications for lipid metabolic disorders. ( 22507046 )
2012
19
Quercetin Protects against Cadmium-Induced Renal Uric Acid Transport System Alteration and Lipid Metabolism Disorder in Rats. ( 22690247 )
2012
20
Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein. ( 21093950 )
2011
21
The model of rat lipid metabolism disorder induced by chronic stress accompanying high-fat-diet. ( 21871127 )
2011
22
Chanarin-Dorfman syndrome: clinical features of a rare lipid metabolism disorder. ( 19250403 )
2009
23
Fat and cholesterol diet induced lipid metabolic disorders and insulin resistance in rabbit. ( 19301228 )
2009
24
[Carbohydrate and lipid metabolism disorders in obese children and adolescents]. ( 15858253 )
2004
25
[Interconnection between insulin resistance and lipid metabolism disorders in obese patients]. ( 12469622 )
2002
26
[Pharmacologic treatment of lipid metabolism disorders]. ( 9214849 )
1996
27
[The evaluation of a method for determining apolipoproteins as a sensitive indicator in assessing lipid metabolic disorder in a population at risk for essential arterial hypertension (EAHT)]. ( 9455355 )
1995
28
[Lipid metabolic disorders and lipid peroxidation in patients with the nephrotic syndrome]. ( 8079411 )
1994
29
[Relationship between lipid metabolism disorders and age of first manifestations of coronary heart disease]. ( 1509793 )
1992
30
[Pathophysiology and therapy of lipid metabolism disorders in kidney diseases]. ( 1921228 )
1991
31
[Restriction polymorphism in patients with lipid metabolism disorders and ischemic heart disease]. ( 1979835 )
1990
32
A lipid metabolic disorder: disseminated lipogranulomatosis; a syndrome with similarity to, and important difference from, Niemann-Pick and Hand-SchA1ller-Christian disease. ( 12975849 )
1952

Variations for Lipid Metabolism Disorder

Expression for Lipid Metabolism Disorder

Search GEO for disease gene expression data for Lipid Metabolism Disorder.

Pathways for Lipid Metabolism Disorder

Pathways related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 ADIPOQ APOA1 APOA5 APOB APOC3 APOE
2
Show member pathways
12.81 ADIPOQ APOA1 APOA5 HMGCR LEP LPL
3
Show member pathways
12.61 APOA1 APOB APOC3 APOE LPL RBP4
4
Show member pathways
12.37 ADIPOQ HMGCR INS LEP PPARG
5
Show member pathways
12.32 APOA1 APOB APOE CRP INS SERPINE1
6
Show member pathways
12.3 APOA1 APOB APOC3 APOE LPL RBP4
8
Show member pathways
12.19 APOA1 APOA5 APOB APOC3 APOE CETP
9 11.92 ADIPOQ INS LEP LPL PPARA PPARG
10 11.86 ADIPOQ INS LEP LPL PPARG
11
Show member pathways
11.78 APOA1 APOB APOE
12 11.63 HMGCR INS LPL PPARG RBP4
13 11.59 ADIPOQ LEP PPARA
14 11.56 ADIPOQ APOA1 APOA5 APOC3 LPL PPARA
15
Show member pathways
11.44 APOA1 APOA5 APOB APOC3 APOE CETP
16
Show member pathways
11.39 APOA1 APOB MTTP
17 11.12 ADIPOQ LEP PPARG
18 11.12 APOA1 APOA5 APOC3 PPARA
19 11.05 ADIPOQ LEP PPARG

GO Terms for Lipid Metabolism Disorder

Cellular components related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.98 APOA1 APOA5 APOB APOE INS LIPC
2 extracellular matrix GO:0031012 9.89 APOA1 APOC3 APOE LPL SERPINE1
3 early endosome GO:0005769 9.84 APOA1 APOB APOC3 APOE
4 high-density lipoprotein particle GO:0034364 9.77 APOA1 APOA5 APOE CETP LIPC
5 low-density lipoprotein particle GO:0034362 9.71 APOA1 APOA5 APOB APOE
6 endocytic vesicle lumen GO:0071682 9.63 APOA1 APOB APOE
7 intermediate-density lipoprotein particle GO:0034363 9.56 APOA1 APOB APOC3 APOE
8 endosome lumen GO:0031904 9.55 APOB INS
9 spherical high-density lipoprotein particle GO:0034366 9.51 APOA1 APOC3
10 discoidal high-density lipoprotein particle GO:0034365 9.48 APOA1 APOE
11 very-low-density lipoprotein particle GO:0034361 9.43 APOA1 APOA5 APOB APOC3 APOE LPL
12 chylomicron GO:0042627 9.1 APOA1 APOA5 APOB APOC3 APOE LPL
13 extracellular exosome GO:0070062 10.22 ADIPOQ APOA1 APOB APOC3 APOE CETP
14 extracellular region GO:0005576 10.2 ADIPOQ APOA1 APOA5 APOB APOC3 APOE
15 extracellular space GO:0005615 10 ADIPOQ APOA1 APOA5 APOB APOC3 APOE

Biological processes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Name GO ID Score Top Affiliating Genes
1 lipid catabolic process GO:0016042 9.98 APOB APOC3 LIPC LPL
2 response to ethanol GO:0045471 9.98 ADIPOQ HMGCR LEP RBP4
3 negative regulation of inflammatory response GO:0050728 9.97 ADIPOQ APOA1 APOE PPARA
4 circadian rhythm GO:0007623 9.97 ADIPOQ LEP MTTP SERPINE1
5 triglyceride metabolic process GO:0006641 9.97 APOA5 APOC3 APOE CETP LPL MTTP
6 cholesterol efflux GO:0033344 9.96 APOA1 APOA5 APOB APOC3 APOE
7 high-density lipoprotein particle remodeling GO:0034375 9.93 APOA1 APOC3 APOE CETP LIPC
8 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.92 ADIPOQ CETP CRP PPARA PPARG
9 low-density lipoprotein particle remodeling GO:0034374 9.91 APOB APOE CETP LIPC LPA
10 glucose metabolic process GO:0006006 9.9 ADIPOQ INS LEP
11 cholesterol transport GO:0030301 9.89 APOA1 APOB CETP LIPC
12 phospholipid transport GO:0015914 9.88 APOA1 CETP MTTP
13 phospholipid efflux GO:0033700 9.88 APOA1 APOA5 APOC3 APOE
14 chylomicron remnant clearance GO:0034382 9.88 APOB APOC3 APOE LIPC
15 negative regulation of MAP kinase activity GO:0043407 9.87 ADIPOQ APOE HMGCR
16 cholesterol biosynthetic process GO:0006695 9.87 APOA1 APOA5 HMGCR
17 very-low-density lipoprotein particle remodeling GO:0034372 9.87 APOE CETP LIPC LPL
18 triglyceride homeostasis GO:0070328 9.87 APOA1 APOA5 APOC3 APOE CETP LIPC
19 lipid homeostasis GO:0055088 9.85 APOE CETP PPARG
20 chylomicron assembly GO:0034378 9.85 APOA1 APOB APOC3 APOE MTTP
21 reverse cholesterol transport GO:0043691 9.85 APOA1 APOA5 APOC3 APOE CETP LIPC
22 lipoprotein transport GO:0042953 9.83 APOB MTTP PPARG
23 high-density lipoprotein particle assembly GO:0034380 9.83 APOA1 APOA5 APOE
24 very-low-density lipoprotein particle assembly GO:0034379 9.83 APOB APOC3 MTTP
25 negative regulation of blood vessel diameter GO:0097756 9.82 CRP HMGCR INS
26 positive regulation of cholesterol esterification GO:0010873 9.82 APOA1 APOA5 APOE
27 neuron projection regeneration GO:0031102 9.81 APOA1 APOA5 APOE
28 regulation of Cdc42 protein signal transduction GO:0032489 9.8 APOA1 APOC3 APOE
29 chylomicron remodeling GO:0034371 9.8 APOA1 APOB APOC3 APOE LPL
30 lipoprotein metabolic process GO:0042157 9.8 APOA1 APOA5 APOB APOC3 APOE MTTP
31 lipoprotein biosynthetic process GO:0042158 9.79 APOA1 APOB APOE
32 regulation of intestinal cholesterol absorption GO:0030300 9.78 APOA1 APOA5 LEP
33 lipid metabolic process GO:0006629 9.77 APOA1 APOB APOC3 APOE CETP HMGCR
34 negative regulation of lipid catabolic process GO:0050995 9.76 APOC3 INS
35 positive regulation of cellular protein metabolic process GO:0032270 9.76 ADIPOQ INS
36 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.76 APOB LPL
37 fatty acid oxidation GO:0019395 9.75 ADIPOQ PPARG
38 negative regulation of blood coagulation GO:0030195 9.75 APOE SERPINE1
39 regulation of fat cell differentiation GO:0045598 9.75 LEP PPARG
40 negative regulation of wound healing GO:0061045 9.75 HMGCR SERPINE1
41 positive regulation of cholesterol efflux GO:0010875 9.75 ADIPOQ APOE
42 negative regulation of smooth muscle cell migration GO:0014912 9.75 ADIPOQ SERPINE1
43 negative regulation of gluconeogenesis GO:0045721 9.75 ADIPOQ INS
44 positive regulation of insulin receptor signaling pathway GO:0046628 9.74 INS LEP
45 fatty acid homeostasis GO:0055089 9.74 APOE INS
46 long-chain fatty acid transport GO:0015909 9.74 APOE PPARG
47 phosphatidylcholine metabolic process GO:0046470 9.74 APOA5 CETP
48 positive regulation of lipid biosynthetic process GO:0046889 9.74 APOE INS
49 positive regulation of fatty acid biosynthetic process GO:0045723 9.74 APOA1 APOA5
50 response to dietary excess GO:0002021 9.74 APOE LEP

Molecular functions related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.88 APOA5 APOB APOE LIPC LPA LPL
2 phospholipid binding GO:0005543 9.83 APOA1 APOA5 APOB APOC3 APOE
3 lipid binding GO:0008289 9.76 APOA1 APOA5 APOB APOC3 APOE CETP
4 phosphatidylcholine binding GO:0031210 9.67 APOA1 APOA5 CETP
5 low-density lipoprotein particle receptor binding GO:0050750 9.67 APOA5 APOB APOE CRP
6 phospholipid transporter activity GO:0005548 9.65 APOA1 CETP MTTP
7 cholesterol binding GO:0015485 9.65 APOA1 APOA5 APOC3 APOE CETP
8 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.63 APOA1 APOA5 APOE
9 apolipoprotein binding GO:0034185 9.62 LIPC LPA LPL MTTP
10 low-density lipoprotein particle binding GO:0030169 9.58 CRP LIPC
11 phospholipase activity GO:0004620 9.57 LIPC LPL
12 lipase inhibitor activity GO:0055102 9.56 APOA1 APOC3
13 lipase binding GO:0035473 9.55 APOA5 APOB
14 lipoprotein particle binding GO:0071813 9.54 APOA1 APOE
15 high-density lipoprotein particle receptor binding GO:0070653 9.52 APOA1 APOC3
16 triglyceride binding GO:0017129 9.51 CETP LPL
17 lipid transporter activity GO:0005319 9.35 APOA1 APOB APOE CETP MTTP
18 cholesterol transporter activity GO:0017127 9.02 APOA1 APOA5 APOB APOE CETP

Sources for Lipid Metabolism Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....